

亞東紀念醫院

Esophageal cancer

化學治療處方集

2008-08 制定

最近修改日期：2014-05

Esophageal cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【P-HDFL】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

1. For medically fit patients,

Cisplatin 35mg/m² ivd 2hrs; D1, D8

[5FU 2600 mg/m² + leucovorin (LV) 300 mg/m²] ivd 24hrs; D1, D8

(LV 與 5FU 放在一起給予)

or LV 300 mg/m² ivd 1hrs, followed by 5FU 2600 mg/m² ivd 24hrs; D1, D8

(Leucovorin 與 5FU 分開給予)

Repeated every three weeks

2. For medically unfit patients,

Cisplatin 30mg/m² ivd 2hrs; D1, D8

[5FU 2000 mg/m² + leucovorin (LV) 300 mg/m²] ivd 24hrs; D1, D8

(LV 與 5FU 放在一起給予)

or LV 300 mg/m² ivd 1hrs, followed by 5FU 2000 mg/m² ivd 24hrs; D1, D8

(Leucovorin 與 5FU 分開給予)

Repeated every three weeks

【Paclitaxel-HDFL】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Paclitaxel 80mg/m² ivd 1hrs; D1, D8

[5FU 2600 mg/m² + leucovorin (LV) 300 mg/m²] ivd 24hrs; D1, D8

or LV 300 mg/m² ivd 1hrs, followed by 5FU 2600 mg/m² ivd 24hrs; D1, D8

Repeated every three weeks

(Paclitaxel 健保不給付)

* (if allergic reaction to Paclitaxel, prolonged infusion time to 90mins)

* For medically unfit patients, reduce 5-FU dose to 2000 mg/m² ivd 24hrs

Esophageal cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【PF】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

1. For medically fit patients,

Cisplatin 75mg/m² ivd 3hrs; D1

5-FU 1000mg/m² ivd 24hrs; D1-D5

Repeated every three weeks

*5-FU infusion can be reduced to 3 or 4 days depending on patient condition

2. For medically unfit patients

Cisplatin 60mg/m² ivd 12hrs; D1

5-FU 800mg/m² ivd 24hrs; D2-D5

Repeated every three weeks

*5-FU infusion can be reduced to 3 or 4 days depending on patient condition

【Cetuximab+PF】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cetuximab 400mg/m² ivd 2hrs for first dose, then 250mg/m² ivd 2hrs weekly

PF 的部分與上述 PF 處方內容相同

Repeated every three weeks

(Cetuximab 健保不給付)

【MPF】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Methotrexate 100mg/m² ivd 90mins; D1

Cisplatin 75mg/m² ivd 12hrs; D1

5-FU 800mg/m² ivd 24hrs; D2-D5

Repeated every three weeks

*5-FU infusion can be reduced to 3 days depending on patient condition

Esophageal cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【FOLFOX】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Oxaliplatin 85mg/m² ivd 2hrs, D1
Leucovorin 300 mg/m² ivd 1hr, D1
5-FU 1200mg/m² ivd 24hrs, D1 and D2
Repeated every 2 weeks
(Oxaliplatin 健保不給付)

【weekly Paclitaxel】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Paclitaxel 80 mg/m² ivd 1hrs, D1, D8
Repeated every 3 weeks
OR (depending on patient's performance status)
Paclitaxel 80 mg/m² ivd 1hrs, D1, D8, D15
Repeated every 4 weeks

【Weekly methotrexate (MTX)】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

For medically fit patients:

MTX 100 mg/m² ivd 90mins; D1, D8, repeated every three weeks

For medically unfit patients:

MTX 40 mg/m² ivd 30mins, weekly

Esophageal cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Ifosphamide-Etoposide(IE)】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Ifosphamide 2000 mg/m² ivd 8hrs, qd, D1-D3

Etoposide 80mg/m² ivd 2hrs, qd, D1-D3

Mesna 700mg/m² ivd q8h, D1-D3

Repeated every 3 weeks

【PFL】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

[Cisplatin 35mg/m² + 5-FU 450mg/m² + leucovorin 50mg/m²] in N/S 250ml iv drip
2hrs(泡在同一包點滴給予)

Or

Cisplatin 35 mg/m² ivd 2hrs, D1

Leucovorin 50mg/m ivd 30mins, D1

5-FU 500mg/m² ivd 30mins, D1

Repeated every week during radiotherapy period

* reduce cisplatin dose to 30mg/m² ivd 2hrs if intolerable

【Cisplatin】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cisplatin 35mg/m² ivd 2hrs, weekly, concomitant with radiotherapy

* reduce cisplatin dose to 30mg/m² ivd 2hrs if intolerable

Esophageal cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Carboplatin-CCRT】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Carboplatin AUC=2 ivd 1hrs, weekly, concomitant with radiotherapy

【Cisplatin-Paclitaxel (TP)】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Paclitaxel 80 mg/m² ivd 1hrs , D1

Cisplatin 30 mg/m² ivd 2hrs, D2

Repeated weekly, concomitant with radiotherapy

(Paclitaxel 健保不給付)

【Cisplatin-MTX (MP) CCRT】

- 化療屬性
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

MTX 40mg/m² ivd 1hrs , D1

Cisplatin 30mg/m² ivd 2hrs, D2

Repeated weekly, concomitant with radiotherapy

References :

1. Ann Oncol. 2014 Mar; 25(3):638-43
2. Anticancer Res. 2002 Nov-Dec;22(6B):3621-7.
3. Ann Oncol. 2002 May; 13(5):721-9.
4. Gan To Kagaku Ryoho. 2013 Nov;40(12):2118-20.
5. Anticancer Res. 2002 Nov-Dec;22(6B):3621-7
6. Ann Oncol. 2007; 18(1): 93-8.
7. Oncology. 2011; 81(3-4): 237-42

Esophageal cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

8. Ann Oncol. 1999 May;10(5):561-7.
9. Eur J Cancer. 1994; 30A(3): 325-8.

亞東紀念醫院 版權所有